Research
Metabolic adaptation
GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease.
Practitioners should be aware of the potential for GLP-1 RAs to address comorbidities in obese OSA patients.
StrongSupportsmedium confidence
GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease, which are commonly associated with OSA.
Why this rating
The claim is supported by the narrative review's focus on GLP-1 RAs and their effects.
Source
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review
Ali El-Solh et al. · Expert Opinion on Pharmacotherapy · 2024
reviewCited 21×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →